Alembic Pharma gets USFDA tentative nod for cancer drug

Alembic Pharma gets USFDA tentative nod for cancer drug — Alembic Pharmaceuticals has received tentative approval from the USFDA for Larotrectinib Capsules, 25 mg and 100 mg. The drug is used for the treatment of certain solid tumors in adults and children. Tentative approval indicates the product meets quality, safety, and efficacy standards, pending final regulatory steps. Commercial launch will follow final approval and patent expiries.
📊 STOCKS: APLLLTD | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA